Epigral Ltd.
Fundamentals
- Market cap
- ₹4,772 cr
- P/E
- 14.38×
- ROE
- 14.94%
- Debt / equity
- 0.25
- Div yield
- 0.44%
- 52-week range
- 807.00 — 2114.00
The timeline — 4 notes on Epigral Ltd.
July 2026
- 27 Jul 26 · 2:18 PM IST Lead Lead · Small cap
Epigral enters epoxy resins with two Dahej plants, capex undisclosed
Board approves a 125,000 TPA epoxy resin plant and a multi-purpose unit, both to be commissioned by H2FY28. The investment amount is not disclosed, leaving scale unmeasured.
- 27 Jul 26 · 2:15 PM IST Lead Lead · Small cap
Epigral bets ₹600 cr on epoxy resins in strategic pivot
The chemicals company posted a 25% profit jump in Q1 and announced a capex equal to 12% of market cap to enter epoxy resins, drawing over half the input value from internal production.
- 27 Jul 26 · 1:59 PM IST Brief Brief · Earnings · Small cap
Epigral Q1: Revenue up 16%, adjusted PAT jumps 24%
Excluding a one-time deferred tax credit in the base quarter, profit rose on volume recovery and sequential margin improvement. The company also incorporated a subsidiary for chemical manufacturing.
- 27 Jul 26 · 1:55 PM IST Brief Brief · Earnings · Small cap
Epigral logs 16% revenue growth in Q1; PAT falls on one-time credit base effect
Revenue hit ₹705 cr, EBITDA margin in line with 25% guidance. PAT slipped to ₹99.18 cr as last year's ₹80.67 cr deferred tax credit didn't repeat.